MCID: GST040
MIFTS: 51

Gastric Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastric Adenocarcinoma

MalaCards integrated aliases for Gastric Adenocarcinoma:

Name: Gastric Adenocarcinoma 12 14 69
Adenocarcinoma of Stomach 12
Stomach Adenocarcinoma 12
Adenocarcinoma Gastric 52

Classifications:



External Ids:

Disease Ontology 12 DOID:3717
NCIt 47 C4004
SNOMED-CT 64 408647009
UMLS 69 C0278701

Summaries for Gastric Adenocarcinoma

Disease Ontology : 12 A stomach carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Gastric Adenocarcinoma, also known as adenocarcinoma of stomach, is related to hepatocellular carcinoma and lung cancer, and has symptoms including dyspepsia An important gene associated with Gastric Adenocarcinoma is CDH1 (Cadherin 1), and among its related pathways/superpathways are Endometrial cancer and Development ERBB-family signaling. The drugs Taxotere and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and bone, and related phenotypes are homeostasis/metabolism and digestive/alimentary

Wikipedia : 72 Stomach cancer, also known as gastric cancer, is cancer developing from the lining of the stomach. Early... more...

Related Diseases for Gastric Adenocarcinoma

Diseases related to Gastric Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 261)
id Related Disease Score Top Affiliating Genes
1 hepatocellular carcinoma 28.1 AFP CDH1 CDH17 CEACAM5 CTNNB1 MYC
2 lung cancer 28.0 CDH1 CEACAM5 CHGA CTNNB1 ERBB2 FHIT
3 gastric adenocarcinoma and proximal polyposis of the stomach 11.9
4 mucinous stomach adenocarcinoma 11.9
5 gastric cancer risk after h. pylori infection 11.1
6 adenocarcinoma 11.0
7 signet ring basal cell carcinoma 10.9 ERBB2 MYC
8 krukenberg carcinoma 10.9
9 bladder tuberculosis 10.9 CDH1 ERBB2
10 ureter squamous cell carcinoma 10.9 CEACAM5 ERBB2
11 gastric papillary adenocarcinoma 10.9
12 gastric tubular adenocarcinoma 10.9
13 autoimmune enteropathy 10.9 CHGA GAST
14 gastric cardia adenocarcinoma 10.9
15 breast sarcoma 10.9 CDH1 CTNNB1 ERBB2
16 rectum kaposi's sarcoma 10.8 CTNNB1 ERBB2 PTGS2
17 skin sarcoma 10.8 CEACAM5 ERBB2
18 primary syphilis 10.8 CHGA GAST
19 penis squamous cell carcinoma 10.8 CDH1 CEACAM5 ERBB2
20 bone giant cell sarcoma 10.8 CHGA GAST
21 normokalemic periodic paralysis 10.8 AFP ERBB2
22 periosteal osteogenic sarcoma 10.8 CTNNB1 KRT20
23 urethral obstruction sequence 10.8 AFP CEACAM5
24 schwannian stroma-rich and stroma-poor composite ganglioneuroblastoma 10.8 ERBB2 FHIT PTGS2
25 kidney benign neoplasm 10.8 CDH1 CEACAM5 ERBB2
26 pulmonary vein leiomyosarcoma 10.8 CEACAM5 CHGA
27 estrogen-receptor negative breast cancer 10.8 CDH1 ERBB2 PTGS2
28 hereditary persistence of fetal hemoglobin, klf1-related 10.8 MLH1 PTGS2
29 frontal sinus schneiderian papilloma 10.8 CDX2 GAST PTGS2
30 desmoid disease, hereditary 10.8 CDH1 CTNNB1 MYC
31 dental caries 10.8 CDH1 CEACAM5 ERBB2
32 nasal cavity disease 10.8 CDH1 CEACAM5 ERBB2
33 clear cell variant infiltrating bladder urothelial carcinoma 10.8 AFP CEACAM5
34 synovitis 10.8 CDX2 CEACAM5
35 sohval soffer syndrome 10.8 CDX2 CTNNB1 ERBB2
36 vulva squamous cell carcinoma 10.8 CEACAM5 ERBB2 KRT20
37 intestine carcinoma in situ 10.7 AFP CEACAM5
38 pineal region meningioma 10.7 CDH1 CDX2 CEACAM5
39 endometriosis of uterus 10.7 CTNNB1 ERBB2 MLH1
40 proliferative type fibrocystic change of breast 10.7 CDX2 CEACAM5 GAST
41 congenital hypomyelination neuropathy 10.7 CTNNB1 MLH1 PTGS2
42 pediatric infratentorial ependymoblastoma 10.7 GAST PTGS2 S100A8
43 mediastinum teratoma 10.7 AFP CHGA
44 neuroendocrine tumor 10.7 CDX2 KRT20 PTGS2
45 ludwig's angina 10.7 CHGA KRT20
46 childhood teratoma of the ovary 10.7 CDH1 CDX2 KRT20
47 gangliosidosis gm1 10.7 AFP MYC
48 pancreatic somatostatinoma 10.7 CDH1 CEACAM5 CTNNB1
49 angioma serpiginosum 10.7 CDH1 KRT20
50 paroxysmal nocturnal hemoglobinuria 10.7 CDH1 CTNNB1 ERBB2

Graphical network of the top 20 diseases related to Gastric Adenocarcinoma:



Diseases related to Gastric Adenocarcinoma

Symptoms & Phenotypes for Gastric Adenocarcinoma

UMLS symptoms related to Gastric Adenocarcinoma:


dyspepsia

MGI Mouse Phenotypes related to Gastric Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 CLDN4 CTNNB1 ERBB2 FHIT GAST MLH1
2 digestive/alimentary MP:0005381 10.14 CCKBR CDH1 CDX2 CTNNB1 ERBB2 FHIT
3 endocrine/exocrine gland MP:0005379 10.11 AFP CCKBR CDH1 CDX2 CHGA CTNNB1
4 mortality/aging MP:0010768 9.97 MLH1 MYC PTGS2 S100A8 AFP CDH1
5 integument MP:0010771 9.86 CCKBR CDH1 CTNNB1 ERBB2 FHIT MLH1
6 neoplasm MP:0002006 9.7 TFF1 AFP CDH1 CDX2 CTNNB1 ERBB2
7 reproductive system MP:0005389 9.32 ROS1 AFP CDH1 CDX2 CHGA CTNNB1

Drugs & Therapeutics for Gastric Adenocarcinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Taxotere 17 46 DOCETAXEL Rhone Poulenc Rorer May 1996

Drugs for Gastric Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
2
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
3
Levoleucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 68538-85-2
4
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
5
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
6
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 180288-69-1 9903
7
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
8
Iron Approved Phase 4 7439-89-6 23925
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 59-30-3 6037
10
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
11
Camptothecin Experimental Phase 4,Phase 2,Phase 1 7689-03-4
12 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
13 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
14 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
15 Antidotes Phase 4,Phase 3,Phase 2,Phase 1
16 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
19 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
22 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1
23 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
25 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
26 Antacids Phase 4
27 Anti-Ulcer Agents Phase 4
28 Gastrointestinal Agents Phase 4
29
Proton pump inhibitors Phase 4
30 Ferric Compounds Phase 4
31 Folate Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
32 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
33
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
34
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
35
Tegafur Approved Phase 3,Phase 2,Phase 1 17902-23-7 5386
36
Epirubicin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 56420-45-2 41867
37
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
38
Pancrelipase Approved Phase 3,Phase 2,Phase 1 53608-75-6
39
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
40
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
41
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
42
Floxuridine Approved Phase 3,Phase 2 50-91-9 5790
43
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
44
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
45
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
46
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
47
Menthol Approved Phase 3,Phase 2 2216-51-5 16666
48
Vinblastine Approved Phase 2, Phase 3 865-21-4 13342 241903
49
Pertuzumab Approved Phase 2, Phase 3 145040-37-5, 380610-27-5 2540
50
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4

Interventional clinical trials:

(show top 50) (show all 467)

id Name Status NCT ID Phase Drugs
1 Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection Completed NCT00844675 Phase 4 rabeprazole;placebo
2 Clinical Outcomes of Endoscopic Resection for Treating WHYX Lesion Completed NCT01451034 Phase 4
3 Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Recruiting NCT02426034 Phase 4 Apatinib
4 Iron Replacement in Oesophagogastric Neoplasia Recruiting NCT01927328 Phase 4 Iron isomaltoside 1000
5 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
6 Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma Terminated NCT00871273 Phase 4 capecitabine
7 A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer Terminated NCT01260194 Phase 4 trastuzumab [Herceptin]
8 Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Unknown status NCT01015339 Phase 3 Paclitaxel;capecitabine;capecitabine;cisplatin
9 Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction Unknown status NCT01468389 Phase 3 Capecitabine;capecitabine
10 SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer Unknown status NCT01583361 Phase 3 Oxaliplatin+S-1;Adjuvant Oxaliplatin/S-1(SOX)
11 Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer Unknown status NCT01283217 Phase 3 DS;SP
12 Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer Unknown status NCT02537171 Phase 3 apatinib
13 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
14 Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Completed NCT01640782 Phase 3 Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
15 Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma Completed NCT00323830 Phase 3 Capecitabine, cisplatin, Radiotherapy (+/-)
16 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed NCT00678535 Phase 3 Cetuximab;Capecitabine;Cisplatin
17 Covered Versus Uncovered Self-expandable Metallic Stents for Malignant Gastric Outlet Obstruction Completed NCT01646476 Phase 3
18 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3 docetaxel;steroid therapy
19 Trial of Adjuvant Chemotherapy for Gastric Cancer Completed NCT00296335 Phase 3 Mitomycin, doxifluridine and cisplatin;Mitomycin and doxifluridine
20 Trial of Adjuvant Chemotherapy for Gastric Cancer Completed NCT00296322 Phase 3 cisplatin, mitomycin-C, doxifluridine
21 A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer Completed NCT02560974 Phase 3 Capecitabine;Oxaliplatin
22 Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer Completed NCT00411229 Phase 3 Capecitabine;Oxaliplatin
23 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed NCT00917384 Phase 3 Placebo
24 Metastatic Gastric Cancer FFCD 03-07 Completed NCT00374036 Phase 3 ECC;FOLFIRI
25 S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer Completed NCT00182611 Phase 3 cisplatin;tegafur-gimeracil-oteracil potassium
26 A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer Completed NCT01662869 Phase 3 5-Fluoruracil;Folinic acid;Onartuzumab;Oxaliplatin;Placebo
27 Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer Completed NCT00002615 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil
28 Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer Completed NCT00020787 Phase 3 cisplatin;fluorouracil
29 Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) Completed NCT00879333 Phase 3 Everolimus;Everolimus placebo;Best Supportive Care (BSC)
30 Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for Adenocarcinoma Completed NCT01491698 Phase 3
31 A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer Completed NCT00548548 Phase 3 Bevacizumab;Capecitabine;Cisplatin;Placebo;5-fluorouracil
32 Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma Completed NCT02445209 Phase 3
33 Phase III Study OF the Gastric Surgery on Advanced Stage Gastric Cancer Completed NCT00260884 Phase 3
34 S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients Recruiting NCT01824459 Phase 3 S-1;Oxaliplatin;Cisplatin
35 Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Recruiting NCT02193594 Phase 2, Phase 3 Adjuvant chemotherapy
36 D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma Recruiting NCT01882933 Phase 3 HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin
37 Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection Recruiting NCT01534546 Phase 3 Oxaliplatin capecitabine;Oxaliplatin S-1;Oxaliplatin S-1
38 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Recruiting NCT02625610 Phase 3 Avelumab;Oxaliplatin;5-Fluorouracil;Leucovorin;Capecitabine;Oxaliplatin;5-Fluorouracil;Leucovorin;Capecitabine
39 Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Recruiting NCT02578368 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Trastuzumab;sodium folinate
40 Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer Recruiting NCT02240524 Phase 3
41 Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer Recruiting NCT02512380 Phase 3 Docetaxel;oxaliplatin;s1;oxaliplatin;s1
42 A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer Recruiting NCT02144727 Phase 3
43 FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer Recruiting NCT02581462 Phase 2, Phase 3 FLOT alone
44 Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial Recruiting NCT01761461 Phase 3 TS-1, oxaliplatin
45 Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer Recruiting NCT03042611 Phase 3 Apatinib
46 Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma Recruiting NCT01711242 Phase 3 Capecitabine;Oxaliplatin
47 Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer Recruiting NCT02289547 Phase 3 Capecitabine
48 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Recruiting NCT02898077 Phase 3 Ramucirumab;Paclitaxel;Placebo
49 Preoperative Stomach Cancer Induction Chemotherapy and Radiation Therapy Recruiting NCT03223740 Phase 3
50 Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer Recruiting NCT01917552 Phase 3 capecitabine

Search NIH Clinical Center for Gastric Adenocarcinoma

Genetic Tests for Gastric Adenocarcinoma

Anatomical Context for Gastric Adenocarcinoma

MalaCards organs/tissues related to Gastric Adenocarcinoma:

39
Lymph Node, Liver, Bone, Lung, Skin, Eye, Breast

Publications for Gastric Adenocarcinoma

Articles related to Gastric Adenocarcinoma:

(show top 50) (show all 1067)
id Title Authors Year
1
Long-term Trends in Primary Sites of Gastric Adenocarcinoma in Japan and the United States. ( 28819392 )
2017
2
Dyskeratosis congenita, bone marrow failure, and gastric adenocarcinoma: an insight into telomere biology. ( 28699608 )
2017
3
Prognostic significance of autophagy-related proteins expression in resected human gastric adenocarcinoma. ( 28224423 )
2017
4
Early gastric adenocarcinoma arising within foveolar-type dysplasia in a patient with Muir-Torre variant Lynch syndrome. ( 28501935 )
2017
5
A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma. ( 28913565 )
2017
6
Iodine Concentration in Spectral CT: Assessment of Prognostic Determinants in Patients With Gastric Adenocarcinoma. ( 28871809 )
2017
7
MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. ( 28836853 )
2017
8
The Nutritive Value of Organic and Conventional White Cabbage (Brassica Oleracea L. Var. Capitata) and Anti-Apoptotic Activity in Gastric Adenocarcinoma Cells of Sauerkraut Juice Produced Therof. ( 28838245 )
2017
9
The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. ( 28948368 )
2017
10
Gastric Adenocarcinoma: A Multimodal Approach. ( 28824918 )
2017
11
Factors associated with gastric adenocarcinoma and dysplasia in patients with chronic gastritis: a population-based study. ( 28947866 )
2017
12
Differentially regulated ADAMTS1, 8, and 18 in gastric adenocarcinoma. ( 28814085 )
2017
13
Gastric adenocarcinoma. ( 28805208 )
2017
14
An unusual primary malignant tumor of the stomach: Fetal gut-like Gastric adenocarcinoma with "blastoma"-like component. ( 28315695 )
2017
15
Prognostic role of BiP/GRP78 expression as ER stress in patients with gastric adenocarcinoma. ( 28854502 )
2017
16
Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. ( 28815316 )
2017
17
An application study of low-dose computed tomography perfusion imaging for evaluation of the efficacy of neoadjuvant chemotherapy for advanced gastric adenocarcinoma. ( 28871423 )
2017
18
Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review. ( 28044374 )
2017
19
CDKN1A histone acetylation and gene expression relationship in gastric adenocarcinomas. ( 26567008 )
2017
20
Tumoral FOXP3 expression is associated with favorable clinicopathological variables and good prognosis in gastric adenocarcinoma; the tumor suppressor function of tumoral FOXP3 is related with the P21 expression in gastric adenocarcinoma. ( 28882702 )
2017
21
Effects of natural phenolic compound carvacrol on the human gastric adenocarcinoma (AGS) cells in vitro. ( 28244942 )
2017
22
Subacute cutaneous lupus erythematosus - paraneoplastic to gastric adenocarcinoma? ( 28421344 )
2017
23
Expression and Significance of Cyclophilin J in Primary Gastric Adenocarcinoma. ( 28739742 )
2017
24
Clinicopathological evaluation of Sox10 expression in diffuse-type gastric adenocarcinoma. ( 27943102 )
2017
25
Correction: Physical activity domains and risk of gastric adenocarcinoma in the MCC-Spain case-control study. ( 28859170 )
2017
26
Gastric Adenocarcinoma with Systemic Metastasis Involving the Intraocular Choroid and Duodenum. ( 28835091 )
2017
27
[Increased expressions of peripheral PD-1(+) lymphocytes and CD4(+)CD25(+)FOXP3(+) T cells in gastric adenocarcinoma patients]. ( 28031121 )
2017
28
Detection and Significance of Human Epidermal Growth Factor Receptor 2 Expression in Gastric Adenocarcinoma. ( 28900323 )
2017
29
Expression of ribophorine II is a promising prognostic factor in human gastric adenocarcinoma. ( 28035352 )
2017
30
Expression and potential roles of sodium-potassium ATPase and E-cadherin in human gastric adenocarcinoma. ( 28832634 )
2017
31
Systemic Inflammation Response Index (SIRI), cancer stem cells and survival of localised gastric adenocarcinoma after curative resection. ( 28828692 )
2017
32
CT/MRI accuracy in detecting and determining preoperative stage of gastric adenocarcinoma in Albania. ( 28947888 )
2017
33
CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2. ( 28029907 )
2017
34
MALAT1 promoted invasiveness of gastric adenocarcinoma. ( 28077118 )
2017
35
Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma. ( 28736638 )
2017
36
Extremely high expression of serum alpha-fetoprotein level of gastric adenocarcinoma: a rare case with an unexpected well-prognosis. ( 27995033 )
2016
37
Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. ( 28078109 )
2016
38
N-Acetyltransferase 2 (NAT2) genetic variation and the susceptibility to noncardiac gastric adenocarcinoma in Taiwan. ( 26617241 )
2016
39
Efficacy of Omega Fatty Acid Supplementation on mRNA Expression Level of Tumor Necrosis Factor Alpha in Patients with Gastric Adenocarcinoma. ( 27170003 )
2016
40
High Tumor Vascular Endothelial Growth Factor Expression Is Associated With Poorer Clinical Outcomes in Resected T3 Gastric Adenocarcinoma. ( 27543975 )
2016
41
Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. ( 26887337 )
2016
42
Clinical and prognosis relevance of COX-2 expression in Tunisian patients with primary gastric adenocarcinoma. ( 27314294 )
2016
43
Preoperative Gross Classification of Gastric Adenocarcinoma: Comparison of Double Contrast-Enhanced Ultrasound and Multi-Detector Row CT. ( 27072076 )
2016
44
Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). ( 27602586 )
2016
45
Tumor volume of resectable gastric adenocarcinoma on multidetector computed tomography: association with N categories. ( 27166769 )
2016
46
The overexpression of MDM4: an effective and novel predictor of gastric adenocarcinoma lymph node metastasis. ( 27626496 )
2016
47
Is targeted therapy possible for patients with gastric adenocarcinoma? ( 27652930 )
2016
48
Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma. ( 27478410 )
2016
49
The Value of miR-299-5p in Diagnosis and Prognosis of Intestinal-Type Gastric Adenocarcinoma. ( 27007598 )
2016
50
Distal Esophageal Adenocarcinoma and Gastric Adenocarcinoma: Time for a Shared Research Agenda. ( 27573764 )
2016

Variations for Gastric Adenocarcinoma

ClinVar genetic disease variations for Gastric Adenocarcinoma:

6 (show top 50) (show all 97)
id Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434498 GRCh37 Chromosome 19, 4117551: 4117551
3 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
4 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
5 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
6 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
7 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
8 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
9 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
10 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
11 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
12 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
13 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
14 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
15 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
16 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
17 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
18 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
19 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Pathogenic/Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
20 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
21 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic/Likely pathogenic rs79184941 GRCh37 Chromosome 10, 123279677: 123279677
22 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
23 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
24 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
25 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
26 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
27 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
28 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
29 KIT NM_000222.2(KIT): c.1924A> G (p.Lys642Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913512 GRCh37 Chromosome 4, 55594221: 55594221
30 ERBB2 NM_001005862.2(ERBB2): c.2173_2174delTTinsCC (p.Leu725Pro) indel Pathogenic/Likely pathogenic rs121913469 GRCh37 Chromosome 17, 37880219: 37880220
31 ERBB2 NM_001005862.2(ERBB2): c.2236G> A (p.Gly746Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28933369 GRCh37 Chromosome 17, 37880997: 37880997
32 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
33 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
34 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
35 RAF1 NM_002880.3(RAF1): c.770C> T (p.Ser257Leu) single nucleotide variant Pathogenic/Likely pathogenic rs80338796 GRCh37 Chromosome 3, 12645699: 12645699
36 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
37 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
38 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
39 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
40 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
41 CTNNB1 NM_001904.3(CTNNB1): c.95A> G (p.Asp32Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913396 GRCh37 Chromosome 3, 41266098: 41266098
42 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
43 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
44 CTNNB1 NM_001904.3(CTNNB1): c.98C> T (p.Ser33Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
45 CTNNB1 NM_001904.3(CTNNB1): c.101G> A (p.Gly34Glu) single nucleotide variant Pathogenic/Likely pathogenic rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
46 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
47 SMAD4 NM_005359.5(SMAD4): c.1081C> G (p.Arg361Gly) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
48 SMAD4 NM_005359.5(SMAD4): c.1082G> A (p.Arg361His) single nucleotide variant Pathogenic/Likely pathogenic rs377767347 GRCh37 Chromosome 18, 48591919: 48591919
49 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
50 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913272 GRCh37 Chromosome 3, 178927980: 178927980

Cosmic variations for Gastric Adenocarcinoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM44126 TP53 skin,eye,carcinoma,NS c.507G>A p.M169I 3
2 COSM43583 TP53 skin,eye,carcinoma,NS c.425C>T p.P142L 3
3 COSM45444 TP53 skin,eye,carcinoma,NS c.587G>T p.R196L 3
4 COSM144245 PTCH1 skin,eye,carcinoma,NS c.1585A>T p.K529* 3
5 COSM498 HRAS skin,eye,carcinoma,NS c.182A>T p.Q61L 3

Copy number variations for Gastric Adenocarcinoma from CNVD:

7 (show all 39)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14963 1 111600000 115900000 Gain C1orf88 Gastric adenocarcinoma
2 14964 1 111600000 115900000 Gain CHIA Gastric adenocarcinoma
3 14966 1 111600000 115900000 Gain OVGP1 Gastric adenocarcinoma
4 33992 1 51300000 56200000 Loss LRP8 Gastric adenocarcinoma
5 38160 10 1 3000000 Gain DIP2C Gastric adenocarcinoma
6 48224 10 99400000 102000000 Gain CHUK Gastric adenocarcinoma
7 48225 10 99400000 102000000 Gain CWF19L1 Gastric adenocarcinoma
8 48226 10 99400000 102000000 Gain SPFH1 Gastric adenocarcinoma
9 48323 11 1 21600000 Gain ST5 Gastric adenocarcinoma
10 66124 12 25358179 25403863 Amplification KRAS Gastric adenocarcinoma
11 80193 13 86500000 88800000 Loss SLITRK5 Gastric adenocarcinoma
12 81497 14 103000000 106368585 Loss IGHV3-22 Gastric adenocarcinoma
13 92520 15 41400000 42700000 Loss CAPN3 Gastric adenocarcinoma
14 92521 15 41400000 42700000 Loss GANC Gastric adenocarcinoma
15 93577 15 55800000 57100000 Gain LDHAL6B Gastric adenocarcinoma
16 93578 15 55800000 57100000 Gain MYO1E Gastric adenocarcinoma
17 97919 16 14700000 16700000 Gain PKD1P3 Gastric adenocarcinoma
18 112023 17 3773917 3814485 Loss ATP2A3 Gastric adenocarcinoma
19 112078 17 37844392 37884914 Amplification Gastric adenocarcinoma
20 112310 17 3854487 3993002 Loss ZZEF1 Gastric adenocarcinoma
21 130603 19 50000000 53800000 Gain Gastric adenocarcinoma
22 135991 12 128122223 128954165 Gain TMEM132D Gastric adenocarcinoma
23 159208 21 41400000 46944323 Loss HSF2BP Gastric adenocarcinoma
24 159209 21 41400000 46944323 Loss KIAA0179 Gastric adenocarcinoma
25 166094 3 1 3500000 Loss CNTN6 Gastric adenocarcinoma
26 169827 3 14700000 23800000 Loss UBE2E1 Gastric adenocarcinoma
27 182313 4 139500000 141700000 Loss MAML3 Gastric adenocarcinoma
28 184256 4 172200000 176600000 Loss Gastric adenocarcinoma
29 195591 5 152100000 155600000 Loss TIMD4 Gastric adenocarcinoma
30 201331 5 68400000 73300000 Gain FCHO2 Gastric adenocarcinoma
31 221297 7 142800000 147500000 Loss CNTNAP2 Gastric adenocarcinoma
32 233707 8 12700000 19100000 Gain Gastric adenocarcinoma
33 236938 8 19100000 23400000 Loss INTS10 Gastric adenocarcinoma
34 237477 8 23400000 27400000 Loss CDCA2 Gastric adenocarcinoma
35 237478 8 23400000 27400000 Loss DOCK5 Gastric adenocarcinoma
36 237479 8 23400000 27400000 Loss GNRH1 Gastric adenocarcinoma
37 237480 8 23400000 27400000 Loss KCTD9 Gastric adenocarcinoma
38 237883 8 27400000 29700000 Loss EXTL3 Gastric adenocarcinoma
39 262032 X 29400000 31500000 Gain XK Gastric adenocarcinoma

Expression for Gastric Adenocarcinoma

Search GEO for disease gene expression data for Gastric Adenocarcinoma.

Pathways for Gastric Adenocarcinoma

GO Terms for Gastric Adenocarcinoma

Cellular components related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 apical junction complex GO:0043296 9.32 CDH1 CTNNB1
2 catenin complex GO:0016342 9.26 CDH1 CTNNB1
3 basolateral plasma membrane GO:0016323 9.26 CDH17 CEACAM5 CTNNB1 ERBB2
4 flotillin complex GO:0016600 9.16 CDH1 CTNNB1
5 lateral plasma membrane GO:0016328 8.8 CDH1 CLDN4 CTNNB1

Biological processes related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.65 CCKBR CDX2 CTNNB1 MYC PTGS2
2 wound healing GO:0042060 9.5 ERBB2 S100A8 TFF1
3 entry of bacterium into host cell GO:0035635 9.16 CDH1 CTNNB1
4 cellular response to indole-3-methanol GO:0071681 8.96 CDH1 CTNNB1
5 adherens junction organization GO:0034332 8.8 CDH1 CDH17 CTNNB1

Molecular functions related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 8.8 CTNNB1 ERBB2 ROS1

Sources for Gastric Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....